These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Monogenic hypercholesterolemias: new genes, new drug targets].
    Author: Mandel'shtam MIu, Vasil'ev VB.
    Journal: Genetika; 2008 Oct; 44(10):1309-16. PubMed ID: 19062528.
    Abstract:
    This review is focused on recent data on structure and functions of PCSK9 proprotein convertase, a newly identified participant in cholesterol metabolism in mammalian organisms, including humans. Proprotein convertase acts as a molecular chaperone for the low density lipoprotein (LDL) receptor, targeting it to the lysosomal degradation pathway. Various mutations increasing the PCSK9 affinity toward the LDL receptor cause autosomal dominant hypercholesterolemia. In contrast, loss-of-function mutations in PCSK9 gene decrease the blood plasma cholesterol level, thus acting as a protection factor against atherosclerosis and coronary heart disease. It is supposed that pharmacological agents inhibiting the interaction between PCSK9 and LDL receptor may substantially amplify the benefits of drugs--statins and cholesterol absorption blockers--in the treatment of all types of hypercholesterolemia, including its widespread multigenic and multifactorial forms.
    [Abstract] [Full Text] [Related] [New Search]